Abacavir, dolutegravir, and lamivudine

(Triumeq®)

Abacavir, dolutegravir, and lamivudine

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormTablet (oral; 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine); PD Tablet (oral; 60 mg of abacavir, 5 mg of dolutegravir, and 30 mg of lamivudine)
Drug ClassIntegrase strand transfer inhibitors and nucleoside analogue reverse transcriptase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Abacavir, dolutegravir, and lamivudine (Triumeq) is indicated for the treatment of HIV-1 infection in adults and pediatric patients aged at least 3 months and weighing at least 6 kg.
  • Information was derived from a study that was a Randomized Controlled Trial comparing Triumeq to another medication regimen consisting of bictegravir, emtricitabine, and tenofovir alafenamide.
  • In terms of safety and effectiveness comparison between the two regimens for treating HIV-1 infection, both were found to be non-inferior with respect to achieving plasma HIV-1 RNA less than 50 copies per mL. Specifically, virological suppression was achieved by 88% of participants in the bictegravir group compared to 90% in the Triumeq group.
  • Adverse events such as nausea were more common with Triumeq use (24%) when compared with its comparator drug combination (11%). Serious adverse events were comparable between groups, while no participants discontinued due to adverse effects in the bictegravir group versus a discontinuation rate of 2% due to such events within those using Triumeq.
  • Drug-related adverse event reporting rates also favored usage of the bictegravir-based regimen over that involving abacavir/dolutegravir/lamivudine, reported by only about three-quarters as many users, that is, 28%, relative to those on this latter therapy who experienced these issues at an incidence rate closer to half, that is, 40%.
  • The study population consisted mainly of adult individuals living with HIV who are free from hepatitis B virus infection or HLA-B*5701 negative status. This suggests that findings may be broadly applicable among similar demographic profiles, but detailed subgroup analyses based on demographics or comorbidities were not provided.